Norvir Articles
New label warnings on use of Roche’s HIV drug Invirase together with Abbott’s Norvir imposed by US FDA; EMEA calls for lower starting dose
22 October 2010
US FDA warns Lilly on insulin API manufacturing violations and Roche and Abbott over HIV combo drug concerns
24 February 2010
Heat-stable Norvir tablet is equivalent to capsule
18 August 2008
Aptivus gives durable response in HIV patients
5 November 2007
Less price flexibility, more innovation: the market dynamics of targeted therapeutics
16 October 2006
BI's Aptivus linked to intracranial bleeding
10 July 2006
Boeh Ingelheim files NDA for tipranavir
1 November 2004
Euro AIDS activists call for Norvir price freeze
11 October 2004
Waxman/Brown call for NIH investigation
11 October 2004
US group welcomes WHO ARV de-listing
16 August 2004
US FDA raps Abbott over Norvir price claim
21 June 2004
Insurer sues Abbott over Norvir price hike
7 June 2004
Canada: patient groups call for import ban
26 April 2004
Abbott under attack over Norvir price hike
16 February 2004
GSK's early-stage HIV drugs show promise
21 July 2003
AIDS group warns over Roche
17 March 2003
Boeh Ingelheim starts two mega-trials
24 February 2003
Boeh Ingelheim's tipranavir for PI resistance
24 February 2003
New data support efficacy of GW433908
24 February 2003
GSK, Vertex unveil new data on HIV prodrug
17 February 2003
Abbott Labs warned over AD reporting
12 August 2002
Abbott cuts HIV/AIDS drug prices further
24 June 2002
CPMP backs new schedule for Roche HIV drug
24 June 2002
BI's tipranavir effective in resistant HIV
11 March 2002
Brazil to step up HIV/ AIDS vaccine R&D
14 January 2002
Initial therapy with Viracept may avoid emergence of HIV "superbugs"
24 December 2001
BI's tipranavir effective as HIV salvage regimen
10 July 2001
Abbott AIDS drugs for Africa "at no profit"
27 March 2001
Vertex and GW start pivotal trials of amprenavir prodrug in HIV
29 November 2000
New generation of anti-HIV drugs unveiled at ICAAC
13 October 1999
CPMP adopts positive opinion on soft-capsule Norvir
12 August 1999
New Norvir capsule cleared in USA
1 July 1999
1st qtr net earnings up 13% for Abbott Labs
13 April 1999
Abbott files for Norvir capsules replacement
6 April 1999
-Abbott's Norvir granted European approval
11 March 1999
US HIV conference data in brief
4 February 1999
Abbott's ABT-378 potent against HIV
2 February 1999
Tackling lipodystrophy after HIV therapy
26 January 1999
Stock Commentary New York
30 July 1998
Abbott Reports Production Problems For Norvir
28 July 1998
Warnings To Be Added To US Propulsid Labeling
1 July 1998
Expanded Warnings For J&J's Hismanal
11 February 1998
Promising Data With New GW Therapies
5 February 1998
Global Anti-HIV Market To Top $5 Billion In 2005
21 January 1998
Can Protease Inhibitor Resistance Be Combatted?
4 November 1997
Combo Therapy With DuPont Merck's Sustiva
20 October 1997
Drug Combo Targets HIV In CNS
16 October 1997
Norvir Success In Pediatric HIV
16 October 1997
Long-Term Efficacy With Agouron's Viracept
15 October 1997
Ritonavir May Have Role In KS Therapy
22 August 1997
"Solid Performance" From Abbott In 1st Qtr
21 April 1997
Saquinavir Subject To MDR Pump Clearance
17 March 1997
Can HIV Be Eliminated?
3 February 1997
Promise With Agouron's Viracept & Roche's Invirase
3 February 1997
Abbott Seeks Pediatric Indication For Norvir
3 February 1997
US 4th Qtr/Year-End Results See Strong Growth
27 January 1997
Record Number Of New Chemical Entities In 1996
20 January 1997
Spanish Health Care Spending On AIDS
13 January 1997
Product News In 1996 Dominated By CNS
23 December 1996
New HIV Drugs Raise Funding Specter In UK
28 October 1996
Changing Relationships For IFPMA
21 October 1996
Crixivan And Invirase Cleared In EU For HIV
14 October 1996
Euro CPMP Plenary Meeting
23 September 1996
First Launch Of Boehringer Ingelheim's Nevirapine
2 September 1996
Norvir Filed In Japan
19 August 1996
Combining Protease Inhibitors In HIV; 1st Data
22 July 1996
Dutch Reimbursement Prices For Epivir And Norvir
10 June 1996
Positive Opinion From CPMP For Abbott's Norvir
3 June 1996
New York Stock Comment
3 June 1996
Record Results At Abbott Labs For 1st-Qtr 1996
15 April 1996
Merck's Crixivan Is Third Protease Inhibitor Cleared
25 March 1996
Norvir Launch Soon As FDA Clears 2nd Protease Inhibitor
11 March 1996
Moves In HIV Therapy As FDA Panel Delivers Verdicts
4 March 1996
Ritonavir Cuts HIV Deaths By Almost Half, Says Study
12 February 1996
Triple Therapies For HIV Provide Encouraging Data
5 February 1996
Showing 1-87 of 87 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
